Lipella Pharmaceuticals Revenue vs. Net Income
| LIPO Stock | 3.11 0.16 5.42% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 449.6 K | Current Value 407.9 K | Quarterly Volatility 201.1 K |
For Lipella Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lipella Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lipella Pharmaceuticals Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lipella Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lipella Pharmaceuticals Common over time as well as its relative position and ranking within its peers.
Lipella |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.88) | Revenue Per Share 0.592 | Quarterly Revenue Growth 0.279 | Return On Assets (0.94) | Return On Equity (1.72) |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lipella Pharmaceuticals Net Income vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lipella Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Lipella Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Lipella Pharmaceuticals Common is rated below average in revenue category among its peers. It is rated second overall in net income category among its peers . At this time, Lipella Pharmaceuticals' Total Revenue is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lipella Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Lipella Revenue vs. Competition
Lipella Pharmaceuticals Common is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 133.72 Million. Lipella Pharmaceuticals adds roughly 449,617 in revenue claiming only tiny portion of equities under Health Care industry.
Lipella Net Income vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Lipella Pharmaceuticals |
| = | 449.62 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Lipella Pharmaceuticals |
| = | (4.62 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Lipella Net Income Comparison
Lipella Pharmaceuticals is currently under evaluation in net income category among its peers.
Lipella Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lipella Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lipella Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Lipella Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Lipella Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -2.8 M | -2.9 M | |
| Operating Income | -4.7 M | -4.5 M | |
| Income Before Tax | -4.6 M | -4.4 M | |
| Total Other Income Expense Net | 127 K | 133.3 K | |
| Net Loss | -2.3 M | -2.2 M | |
| Net Loss | -4.6 M | -4.4 M | |
| Income Tax Expense | 5.00 | 5.25 | |
| Net Interest Income | 81.6 K | 85.7 K | |
| Interest Income | 97.2 K | 102 K | |
| Net Loss | -4.3 M | -4.1 M | |
| Change To Netincome | 870.6 K | 914.1 K | |
| Net Loss | (0.77) | (0.73) | |
| Income Quality | 0.68 | 0.48 | |
| Net Income Per E B T | 1.15 | 1.13 |
Lipella Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lipella Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lipella Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lipella Pharmaceuticals' important profitability drivers and their relationship over time.
Use Lipella Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipella Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Lipella Pharmaceuticals Pair Trading
Lipella Pharmaceuticals Common Pair Trading Analysis
The ability to find closely correlated positions to Lipella Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipella Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipella Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipella Pharmaceuticals Common to buy it.
The correlation of Lipella Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipella Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipella Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipella Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lipella Pharmaceuticals position
In addition to having Lipella Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Raw Materials Thematic Idea Now
Raw Materials
Companies that are involved with the development and processing of raw materials such as silver or forestry. The Raw Materials theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Raw Materials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
To fully project Lipella Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lipella Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lipella Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.